Navigation Links
Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence
Date:5/30/2008

CHAPEL HILL, N.C., May 30 /PRNewswire/ -- Given the increasing challenges to patent protection and new product approvals, pharmaceutical companies continue to seek external opportunities to grow their pipelines. With the increasing merger and acquisition activity, industry experts have found the importance of proper integration of assets to be key in obtaining value as described in the newly published study, "M&A Integration Excellence: What Bio- Pharma Companies Need to Know." Best Practices, LLC recently completed this new study utilizing benchmark metrics and executive insights to assess current trends and future directions of bio-pharmaceutical M&A activity and keys to obtaining asset value through optimal integration.

In a benchmarking study that included such influential companies as Pfizer, Lilly, Johnson & Johnson and Abbott, it was found that managing cultural issues was both highly important and extremely difficult to optimize. Integration experts discussed methods for managing such issues through proper planning and execution as described in the study report.

For a complimentary summary of the full report "M&A Integration Excellence: What Bio-Pharma Companies Need to Know," click on the following link http://www3.best-in-class.com/rr952.htm.

Other key topic areas in the research include:

- Structure for Integration

- Pre-Integration Planning Activities

- Integration Risk Management

- Integration Functional Excellence

- Communications Excellence

- Understanding & Managing Cultural Issues

- Post-Deal Closure Integration Activities

- Trends in M&A Integration

Among the key topics gathered in this report are:

- Industry Integration Functional Efficacy

- Efficacy of Integration Structural Approaches

- Integration Planning Initiation

- Pre-Integration Planning Activity Efficacy

- Integration Planning Activity Resource Intensity

- Integration Risk-Assessment Factor Importance

- Integration Approach Assessments

- Post-Deal Closure Integration Ownership

- Time to Integration Stability By Organization Size

- Performance Indicators for Integration Performance Measurement

For more information on this report, contact Robert Naylor at rnaylor@best-in-class.com or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr952.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
2. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
3. Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou
4. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
5. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
6. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Diplomat Specialty Pharmacy Sponsors National Managed Care Roundtable for Industry Executive Advisory Board
9. Dow AgroSciences, Martek Biosciences Form Alliance to Bring Omega-3 Fatty Acids to Food Industry
10. Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry
11. Record Venture Capital and Heated Deal Environment Propel Global Biotechnology Industry Forward in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):